Skip to content
Fontolizumab
Fontolizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against interferon gamma.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Rheumatoid arthritisD001172EFO_0000685M06.9—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFONTOLIZUMAB
INNfontolizumab
Description
Fontolizumab (humanized mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID326859-36-3
RxCUI—
ChEMBL IDCHEMBL2108459
ChEBI ID—
PubChem CID—
DrugBankDB05111
UNII ID6J92H2439Z (ChemIDplus, GSRS)
Target
Agency Approved
IFNG
IFNG
Organism
Homo sapiens
Gene name
IFNG
Gene synonyms
NCBI Gene ID
3458
Protein name
interferon gamma
Protein synonyms
IFN-gamma, Immune interferon
Uniprot ID
Q53ZV4
Mouse ortholog
Ifng (15978)
interferon gamma (Q542B8)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 158 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details